Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May:79:100799.
doi: 10.1016/j.resmer.2020.100799. Epub 2020 Nov 6.

COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib

E Caradec  1 , D Mouren  1 , M Zrounba  1 , L-D Azoulay  1 , C Blandin  1 , S Ivanoff  2 , V Levy  2 , P-Y Brillet  3 , H Nunes  4 , Y Uzunhan  5
Affiliations
Case Reports

COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib

E Caradec et al. Respir Med Res. 2021 May.
No abstract available

Keywords: Covid-19; Idiopathic pulmonary fibrosis; JAK inhibitors; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chest computed tomography. A. September 2019; B. March 2020; C. April 2020.
See this image and copyright information in PMC

References

    1. Liu J., Zheng X., Tong Q., et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020;92(5):491–494. doi: 10.1002/jmv.25709. - DOI - PMC - PubMed
    1. Vannucchi A.M., Guglielmelli P. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? Hematology. 2017;2017(1):480–488. doi: 10.1182/asheducation-2017.1.480. - DOI - PMC - PubMed
    1. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–1034. doi: 10.1016/S0140-6736(20)30628-0. - DOI - PMC - PubMed
    1. Zhang W., Zhao Y., Zhang F., et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393. - DOI - PMC - PubMed
    1. Russell B., Moss C., George G., et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancer Med Sci. 2020;14:1022. doi: 10.3332/ecancer.2020.1022. - DOI - PMC - PubMed

LinkOut - more resources